Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» ANPMF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ANPMF Guru Trades in Q2 2013

Arnold Schneider 12,500 sh (unchged)
» More
Q3 2013

ANPMF Guru Trades in Q3 2013

Arnold Schneider 12,500 sh (unchged)
» More
Q4 2013

ANPMF Guru Trades in Q4 2013

Arnold Schneider 12,500 sh (unchged)
» More
Q1 2014

ANPMF Guru Trades in Q1 2014

Arnold Schneider 12,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ANPMF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Angiotech Pharmaceuticals, Inc. is a pharmaceutical and medical device company that develops, manufactures and markets medical device products and technologies, primarily within the areas of interventional oncology, wound closure and ophthalmology. The Company currently operates in two segments: Medical Device Technologies and Licensed Technologies. Its Medical Device Technologies segment generates the majority of its revenue, develops, manufactures and markets a wide range of single use medical device products, as well as precision manufactured medical device components. These products and components are sold directly to hospitals, clinics, physicians and other end users, as well as to medical products distributors or other third-party medical device manufacturers. Its Licensed Technologies segment includes certain of its legacy technologies for which research and development activities have been concluded. This segment generates additional revenue in the form of royalties received from partners who have licensed and utilize these technologies in their medical device product lines. The Medical Device Technologies segment manufactures and markets single-use specialty medical device products and medical device components. These products are sold directly to end users or other third-party medical device manufacturers. This segment contains significant manufacturing capabilities as well as specialized direct and indirect sales and distribution capabilities. Many of its medical products are made using proprietary manufacturing processes and may be protected by its patent portfolio or proprietary know-how. Its significant product groups within this business segment include Interventional Oncology, Wound Closure, Ophthalmology and Medical Device Components. The Licensed Technologies segment includes certain of its legacy technologies for which research and development activities have been concluded. This segment generates additional revenue in the form of royalties received from partners who have licensed and utilize these technologies in their medical device product lines. Its principal revenues in this segment to date have been royalties derived from sales by its partner BSC of TAXUS paclitaxel-eluting coronary stents for the treatment of coronary artery disease. The Company markets and sells various medical device products through a group of specialized sales organizations that consist of direct sales and marketing personnel, which in some cases are supplemented by independent sales representatives and independent medical products distributors, depending on the product category, customer base or geographic location. The research and development, manufacturing, labeling, advertising, sale, marketing and third-party reimbursement of its medical device products and those of the Company's suppliers, customers and partners are subject to extensive regulation by the FDA, the U.S. Department of Health and Human Services Centers for Medicar

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide